Zoliflodacin is under clinical development by Entasis Therapeutics and currently in Phase III for Uncomplicated Cervical And Urethral Gonorrhea. According to GlobalData, Phase III drugs for Uncomplicated Cervical And Urethral Gonorrhea does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Zoliflodacin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zoliflodacin (ETX-0914 (formerly AZD-0914)) is under development for the treatment of drug-resistant uncomplicated cervical and urethral gonorrhea. The drug candidate is administered through oral route as an antimicrobial amorphous nonsterile powder. The drug candidate is a benzisoxazole derivative and it acts by targeting ATP pocket of DNA gyrase and topoisomerase IV.
Entasis Therapeutics overview
Entasis Therapeutics (Entasis) is a drug development company. It discovers and develops anti-infective therapies for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, ETX0282, ETX0462 and Zoliflodacin. Its ETX2514 product is a potent inhibitor of class A, C, and D beta-lactamases intended to treat serious gram-negative infections. The company’s pipeline products are used to treat multidrug-resistant gram-negative infections such as pseudomonas aeruginosa, acinetobacter baumanii, carbapenem-resistant enterobacteriaceae, and neisseria gonorrhoeae, among others. It also develops robust clinical and pre-clinical pipeline of medicines. Entasis is headquartered in Waltham, Massachusetts, the US.
For a complete picture of Zoliflodacin’s drug-specific PTSR and LoA scores, buy the report here.